No impact of tenofovir/emtricitabine in estradiol exposure among transwomen on oral PrEP: results from the 12-week drug-drug interaction PrEParadas substudy

Authors :: Cattani, V.
Jalil, E.
Torres, T.
Cardoso, S.
Eksterman, L.
Castro, C.
Monteiro, L.
Anderson, P.
Wilson, E.
Grinsztejn, B.
Veloso, V.
Estrela, R.
Source :: Journal of the International AIDS Society. July, 2021, Vol. 24 Issue S4, p30, 2 p.
Publication Year :: 2021
Abstract: Background: An important HIV prevention barrier for transwomen (TGW) is the concern that oral PrEP containing tenofovir (TDF) and emtricitabine (FTC) negatively affects the efficacy of feminizing hormone therapy (FHT). [...]

Subjects :: Estradiol -- Complications and side effects
Women patients -- Drug therapy
Hormone therapy -- Complications and side effects
Pharmacology, Experimental
Transgender people -- Drug therapy
Drug interactions -- Research
Tenofovir -- Dosage and administration -- Complications and side effects
Emtricitabine -- Dosage and administration -- Complications and side effects
Health

Full Text Access

Tools